InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
September 30, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
September 20, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
July 07, 2021 07:30 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
June 22, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
June 11, 2021 16:11 ET
|
Sorrento Therapeutics, Inc.
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study
May 11, 2021 07:01 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
April 28, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...
AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
March 22, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
January 21, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
November 30, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination Trial DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....